Brooks and Capehart on Trump’s approval ratings and mental acuity

President Trump has launched a public push on affordability and drug prices as his economy approval ratings remain soft (overall approval cited near 42%), but commentators say rhetoric and bellicosity undermine efforts to reset the political narrative. The DOJ’s phased release of heavily redacted Epstein files and a controversial move to place Trump’s name on the Kennedy Center underscore heightened political and legal uncertainty; references to tariffs and executive assertions of power increase policy unpredictability that could feed investor risk premia rather than deliver immediate market-moving developments.

Analysis

Market structure: Political rhetoric focused on affordability, drug pricing and tariffs increases the probability of targeted policy action against pharma and imported consumer goods. Expect pharma gross-margin compression of 200–400bps risk if a drug-pricing negotiation rule (or price caps) gains traction within 3–9 months; retailers with high import intensity (apparel, toys) face 5–10% margin pressure if tariffs rise 5–15%. Big-tech ad platforms (GOOGL/GOOG) are exposed to regulatory headlines but remain insulated near-term given durable ad secular trends.

Risk assessment: Tail risks include accelerated drug-pricing legislation (10–30% chance in 6–12 months), a trade escalation raising input costs across industrials (10%+ immediate shock to relevant import-heavy EBITDA), or politicized regulatory action vs Big Tech (low-medium prob but high impact). Short-term (days) expect headline-driven volatility; medium-term (weeks–months) policy windows and DOJ document releases are catalysts; long-term (quarters) fracturing of global supply chains would change capex and FX flows.

Trade implications: Anticipate flows into defensives and Treasuries on heightened political noise: a 10–20bp move lower in 10‑yr yields is plausible within 48–72 hours after a major escalation, lifting duration instruments. Options volatility (SPX, XLF, XLY) should seasonally reprice; prefer targeted put spreads on exposed sectors rather than broad shorts. Cross-asset: USD safe-haven bid on acute uncertainty, oil mostly idiosyncratic but tariffs could push industrial metals higher.

Contrarian angles: Consensus underprices the speed of pharma margin compression and overprices systemic risk to mega-cap tech; a 5% tech pullback would be buying opportunity for GOOG/GOOGL given cashflows and AI monetization. Historical parallel: 2018 trade threats produced 8–20% sector rotations but limited long-term earnings destruction; trade-sized tactical shorts in retail or big pharma can pay off quickly but reverse if legislation stalls.

Key Decisions for Investors

• Establish a 2% portfolio short relative exposure to consumer discretionary vs staples: implement by shorting XLY (1.5%) and longing XLP (1.5%), horizon 3–6 months; rational: affordability narratives + tariff risk likely to reprice discretionary multiples by 5–10% if consumer demand softens.
• Initiate a 1–2% tactical long position in TLT (or 2–3% notional via 3‑month T‑bond futures) if 10‑yr yield falls >15bps within 72 hours of a major political/legal headline; rational: safe‑haven re-rating during headline risk will compress yields and benefit duration instruments.
• Open a 1% short or buy 3‑month put spreads on large-cap pharma (e.g., PFE 3‑month 10% OTM puts) sized to cap loss at ~1% portfolio; rational: elevated probability of drug‑pricing measures within 90 days can compress multiples and margins by 200–400bps.
• Add a 1–2% long position in GOOGL (Alphabet Class A) on any >5% pullback over a 30‑day window, taking advantage of potential overreaction to political rhetoric; rational: secular ad/AI revenue drivers and strong balance sheet make this a lower-risk contrarian play versus legacy media names such as NYT.